The efficacy of botulinum toxin type A treatment and surgery for acute acquired comitant esotropia.
AACE
BTXA
acute acquired comitant esotropia
botulinum toxin type A
surgical outcome
surgical outcome acute acquired comitant esotropia
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
05
2023
accepted:
18
07
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
To compare the long-term efficiency of botulinum toxin type A (BTXA) injection and surgery on acute acquired comitant esotropia (AACE). This retrospective study enrolled patients with AACE from January 2020 to August 2022. The horizontal angle of deviation pre- and post-treatment was measured. Deviations in BTXA and surgical treatment were compared. The BTXA group was divided into adequate treatment (AT) and inadequate treatment (inAT) subgroup based on the deviation of no more than 4 prism diopters (at near and distance) or temporary exotropia at the 2 week follow-up. The two subgroups were compared to determine the long-term efficacy of BTXA treatment. Ninety-two patients with AACE were included. Follow-up was 6 months. The deviations of the surgery and BTXA group were significantly smaller at the 6 month follow-up than at pre-treatment ( Surgery and BTXA successfully treat AACE. Surgery has a more precise and lasting therapeutic effect than BTXA. AACE patients adequately treated with BTXA and with deviations of no more than 4 prism diopters at 2 weeks follow-up had better outcomes.
Identifiants
pubmed: 37601790
doi: 10.3389/fmed.2023.1219419
pmc: PMC10436330
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1219419Informations de copyright
Copyright © 2023 Li, Tong, Chen, Zhang, Wan, Yin and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ophthalmic Plast Reconstr Surg. 2004 May;20(3):181-5
pubmed: 15167723
Int J Ophthalmol. 2022 Nov 18;15(11):1845-1851
pubmed: 36404961
BMC Ophthalmol. 2021 Jan 18;21(1):45
pubmed: 33461540
Br J Ophthalmol. 1989 Aug;73(8):636-8
pubmed: 2765443
BMC Ophthalmol. 2016 Apr 09;16:37
pubmed: 27061181
BMC Ophthalmol. 2019 Aug 7;19(1):173
pubmed: 31391009
Ophthalmology. 2004 Jun;111(6):1255-62
pubmed: 15177982
Medicine (Baltimore). 2017 Nov;96(46):e8528
pubmed: 29145257
Ophthalmology. 2023 May;130(5):525-532
pubmed: 36572256
Sci Rep. 2019 Sep 25;9(1):13869
pubmed: 31554874
Am J Ophthalmol. 2012 Mar;153(3):560-3
pubmed: 21996305
Trends Biochem Sci. 2002 Nov;27(11):552-8
pubmed: 12417130
J Pediatr Ophthalmol Strabismus. 2020 Jul 1;57(4):251-256
pubmed: 32687210
BMC Ophthalmol. 2020 Nov 25;20(1):464
pubmed: 33238930
Comput Math Methods Med. 2022 Apr 23;2022:5001594
pubmed: 35502413
Graefes Arch Clin Exp Ophthalmol. 2021 Dec;259(12):3787-3794
pubmed: 34319423
J AAPOS. 2010 Apr;14(2):111-6
pubmed: 20451851
Am J Ophthalmol. 1958 Apr;45(4 Pt 2):55-64
pubmed: 13520873
Indian J Ophthalmol. 2022 Apr;70(4):1359-1364
pubmed: 35326055
Int Ophthalmol. 2023 Feb;43(2):567-574
pubmed: 35994189
Am J Ophthalmol. 2017 Apr;176:33-39
pubmed: 28057455
Curr Opin Ophthalmol. 2010 Sep;21(5):361-6
pubmed: 20651594
J Ophthalmol. 2020 Dec 31;2020:1702695
pubmed: 33520294